Navigation Links
Ondine Biomedical’s MRSAID(TM) Technology Demonstrates Successful Results in Reducing Surgical Site Infections
Date:12/12/2012

Vancouver, BC, Canada (PRWEB) December 12, 2012

The MRSAid photodisinfection project, an innovative non-pharmaceutical pilot program conducted over the course of 12 months at Vancouver General Hospital (VGH), has proven successful in reducing surgical site infections (SSIs) by 39 per cent, according to results released by VGH. Under this innovative project, patients undergoing major surgeries at VGH, including cardiac, spinal, orthopedic, thoracic, vascular, breast reconstruction, and neurological surgeries, were treated with MRSAid nasal decolonization therapy prior to surgery. Photodisinfection therapy combined with chlorhexidine body wipes were shown to significantly decrease a patient’s load of Methicillin resistant staphylococcus aureus (MRSA) and Methicillin sensitive staphylococcus aureus (MSSA) on their skin and in their nasal cavity. The pilot is the first of its kind and has saved the Vancouver General Hospital an estimated $1.9 million in costs associated with treating patients who develop SSIs.

“By using these two therapies in conjunction, we were able to reduce SSI occurrences by 39 per cent over the study’s duration which marks impressive gains for patient quality and safety,” said Dr. Elizabeth Bryce, Regional Medical Director, Infection Control at Vancouver Coastal Health. “Most importantly, the decrease in SSIs translates into less morbidity for our patients.”

Patients that develop infections after surgery are five times more likely to be readmitted to a hospital, and twice as likely to die. On average, SSIs require an extended hospital stay of eight days in an acute care setting, and adds hundreds of millions of dollars in additional costs to the Canadian healthcare system every year. The MRSAid photodisinfection pilot which treated more than 5000 patients saw a decrease in SSIs from 4 to 1.25 cases per month, resulting in the freeing of 533 patient beds and an addition of 138 surgeries performed. During the course of the study actual occurrences of SSIs dropped from 85 to 50 cases.

“The results of this project mark a global first for photodisinfection as a non-antibiotic approach to significant reductions in surgical site infections, one of the leading sources of healthcare associated infections,” said Carolyn Cross, Chairman and CEO of Ondine Biomedical Inc., the global leader of photodisinfection technologies. “As a partner in this initiative, we want to thank the dedicated team members at VGH for their pioneering work in the field of non-antibiotic infection control and patient safety, and for their willingness to champion innovation and change.”

Preliminary results on MRSAid nasal decolonization have been presented at two infectious disease conferences. Dr. Titus Wong and his team at Vancouver General Hospital (VGH) won the John Conly Innovation Academy Award at the AMMI - CACMID Annual Conference for their implementation of a universal nasal decolonization program.

“We are proud to be the first hospital in Canada and in North America to implement a program using this combined approach of innovative light-activated technology that will prevent patients from contracting infections post-surgery,” said Dr. Titus Wong, Medical Microbiologist, Vancouver General Hospital. “Not only will this new approach prevent infections and reduce costs, but it will also allow us to reinvest that saved money into direct patient care.”

###
About Ondine Biomedical Inc.
Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on developing leading edge products utilizing its patented light-activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a research and development laboratories in Bothell, Washington, USA and Minneapolis, Minnesota. Please visit the Company's website at: http://www.ondinebio.com and http://www.ondineblog.com. For further information please contact us at: Ondine Biomedical Inc. info(at)ondinebio(dot)com

About Vancouver Coastal Health
Vancouver Coastal Health provides a full range of health care services, ranging from hospital treatment to community-based residential, home health, mental health and public health services. VCH is responsible for the delivery of $3 billion in care to residents of Vancouver, North Vancouver, West Vancouver, Richmond, and in the coastal mountain communities. http://www.vch.ca.

Read the full story at http://www.prweb.com/releases/OndineBio/12/prweb10229844.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Milo Biotechnology Announces FDA Orphan Drug Designation for AAV1-FS344 for Treatment of Duchenne and Becker Muscular Dystrophy
2. SPIE Urges Congress, President to Avoid Fiscal Cliff and Support Science and Technology to Strengthen Economy
3. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
4. A Sewage Treatment Plant Goes Underground Using In-Pipe Technology Company, Inc. Bioaugmentation
5. Bluechiip Licenses Its Technology in Deal with US Tech Company MiTeGen
6. PathoGenetix Names Ann Merrifield as Chief Executive Officer and Prepares to Launch Unique Bacterial Identification Technology
7. Chemical Publishing Company Announces its Niche Catalog in the Water Technology and Water Treatment Space
8. Global Agricultural Biotechnology Industry
9. Fast forward to the past: NASA technologists test game-changing data-processing technology
10. Researchers improve technology to detect hazardous chemicals
11. MiMedx Group to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Spain , Dec. 8, 2016  Anaconda BioMed ... the development of the next generation neuro-thrombectomy system for ... appointment of Tudor G. Jovin, MD to join its ... serve as a strategic network of scientific and clinical ... the development of the ANCD BRAIN ® to ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... launch of flexible packaging for their exceptionally efficient human mesenchymal stem/stromal cell ... RoosterBio’s portfolio of bioprocess media products engineered to radically streamline culture processes, ...
(Date:12/8/2016)... , ... December 08, 2016 , ... This CAST literature ... for biotech crops. The authors focus on the economic effects in countries that are ... of new biotech crops and the resultant risk of low level presence (LLP) puts ...
(Date:12/8/2016)... , Dec. 8, 2016 Soligenix, Inc. ... company focused on developing and commercializing products to treat ... announced today that it will be hosting an Investor ... ET on the origins of innate defense regulators (IDRs) ... review of oral mucositis and the recently announced and ...
Breaking Biology Technology:
(Date:11/17/2016)... CITY OF INDUSTRY, Calif. , Nov. 17, 2016  AIC announces that it ... about using NVMe storage servers in organizations that require high-performance scale-out plus high speed data transfer ... ... ... Setting ...
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
(Date:11/14/2016)... SARASOTA, Fla., Nov. 14, 2016  xG Technology, Inc. ... in providing critical wireless communications for use in challenging ... ended September 30, 2016. Management will hold a conference ... at 5:00 p.m. Eastern Time (details below). ... announced a $16 million binding agreement to acquire Vislink ...
Breaking Biology News(10 mins):